Pursuit Vascular, Inc. today announced it will be showcasing the company’s premier ClearGuard HD cap at two nephrology conferences taking place this month.
| MAPLE GROVE, Minn., Oct. 17, 2018 /PRNewswire/ -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced it will be showcasing the company’s premier ClearGuard HD cap at two nephrology conferences taking place this month – the American Society of Nephrology (ASN) Kidney Week and the National Renal Administrators Association (NRAA) Annual Meeting. ClearGuard HD caps have been proven in major studies to prevent central line-associated bloodstream infections (CLABSIs) in hemodialysis catheter hubs.
ASN Kidney Week, the world’s largest nephrology meeting, brings together over 13,000 kidney professionals from across the globe to learn about the latest advances in the nephrology field and serves as a major forum for disseminating advances in clinical practice, patient care and basic, clinical and translational research. Results from the second major clinical trial demonstrating a reduction of ~70% in CLABSIs using ClearGuard HD caps were published earlier this year in the Society’s Journal of the American Society of Nephrology (JASN). The conference takes place this year at the San Diego Convention Center October 23-28, 2018. Pursuit Vascular will be exhibiting at booth #1922 during exhibition hours. The NRAA Annual Meeting is the largest gathering of renal administrators in the United States. The meeting features leading experts in the kidney care community and dialysis business world to gain insights on the state of the dialysis industry as well as how leading experts are improving patient care. Pursuit Vascular will be participating in the exhibits at booth #211 during exhibition hours. About the ClearGuard HD Antimicrobial Barrier Cap The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter hub. The caps are simple to use and clinically shown to reduce central line-associated bloodstream infection. This simple, yet revolutionary single-use device is protected by 8 issued U.S. patents, and several other U.S. patents pending. Foreign patents issued and pending. For more information, visit www.clearguardhd.com. About Pursuit Vascular Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. (www.pursuitvascular.com) is developing a family of innovative products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the costs of health care. Connect with us at www.pursuitvascular.com and on Twitter at @ClearGuardHD.
SOURCE Pursuit Vascular, Inc. |
View original content to download multimedia:
